BioCentury
ARTICLE | Clinical News

Neogenix Oncology preclinical data

April 25, 2011 7:00 AM UTC

In mouse xenograft models of solid tumors, NEO-201 significantly reduced tumor growth vs. a control IgG antibody (p=0.0034). NEO-201 is human mAb that the company said appears to target a variant of ...